Related Experiment Video
Updated: May 27, 2026

Generating Whole Bacterial Genomes from Clinical Samples using a Target Enrichment Workflow
Published on: August 15, 2025
Mycoplasma genitalium: should we treat and how?
Lisa E Manhart1, Jennifer M Broad, Matthew R Golden
1Departments of Epidemiology, University of Washington, Center for AIDS and STD, 325 9th Ave, Box 359931, Seattle, WA 98104, USA. lmanhart@u.washington.edu
Abstract:
Mycoplasma genitalium is associated with acute and chronic urethritis in men. Existing data on infection in women are limited and inconsistent but suggest that M. genitalium is associated with urethritis, cervicitis, pelvic inflammatory disease, and possibly female infertility. Data are inconclusive regarding the role of M. genitalium in adverse pregnancy outcomes and ectopic pregnancy. Available data suggest that azithromycin is superior to doxycycline in treating M. genitalium infection. However, azithromycin-resistant infections have been reported in 3 continents, and the proportion of azithromycin-resistant M. genitalium infection is unknown. Moxifloxacin is the only drug that currently seems to uniformly eradicate M. genitalium. Detection of M. genitalium is hampered by the absence of a commercially available diagnostic test. Persons with persistent pelvic inflammatory disease or clinically significant persistent urethritis or cervicitis should be tested for M. genitalium, if possible. Infected persons who have not previously received azithromycin should receive that drug. Persons in whom azithromycin therapy fails should be treated with moxifloxicin.
Insights
Mycoplasma genitalium infections can cause urethritis and pelvic inflammatory disease in both men and women. Azithromycin resistance is a growing concern, making moxifloxacin a key treatment option.
Area of Science:
- Infectious Diseases
- Microbiology
- Sexual Health
Background:
- Mycoplasma genitalium is linked to urethritis in men and potentially cervicitis, pelvic inflammatory disease, and infertility in women.
- Current data on M. genitalium's role in female reproductive health and pregnancy outcomes are limited and inconsistent.
- Azithromycin is generally effective, but rising resistance necessitates alternative treatment strategies.
Purpose of the Study:
- To review the current understanding of Mycoplasma genitalium infections.
- To discuss diagnostic challenges and treatment options, including emerging antibiotic resistance.
- To provide guidance on testing and management of M. genitalium infections.
Main Methods:
- Literature review of existing studies on Mycoplasma genitalium epidemiology, clinical associations, and treatment efficacy.
- Analysis of data regarding antibiotic resistance patterns, particularly to azithromycin.
- Evaluation of diagnostic limitations and recommendations for clinical practice.
Main Results:
- Mycoplasma genitalium is a significant cause of urethritis in men and is associated with various gynecological conditions in women.
- Azithromycin resistance is a documented issue globally, impacting treatment effectiveness.
- Moxifloxacin demonstrates high efficacy in eradicating M. genitalium, including resistant strains.
- A lack of commercially available diagnostic tests hinders widespread detection.
Conclusions:
- Mycoplasma genitalium requires careful consideration in the diagnosis and management of urogenital infections.
- Testing for M. genitalium is recommended for persistent urethritis, cervicitis, or pelvic inflammatory disease.
- Treatment guidelines should account for azithromycin resistance, prioritizing moxifloxacin for treatment failures or suspected resistance.
Related Concept Videos
Sexually Transmitted Infections
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Acute Pyelonephritis II: Diagnostic Studies and Management
Microbiota of the Urogenital Tract
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Urinary Tract Infection IV: Nursing Management
